We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Potential Cancer Drug That Kills Infected Cells by Stopping Glucose Supply Shows Promise Against COVID-19

By HospiMedica International staff writers
Posted on 23 Oct 2020
Print article
A potential cancer drug that works by preventing the supply of glucose molecules to the cancerous cells has shown efficacy on COVID-19 patients in clinical trials.

The drug, 2-Deoxy-D-Glucose oral powder, also called 2-DG, prevents the supply of glucose molecules to the cancerous cells, which are dependent on glucose for survival. The cancerous cells begin to die after the drug stops the glucose supply. 2-DG is not yet approved for cancer treatment but demonstrated efficacy on COVID-19 patients in the Phase 2 trial.

The results of the Phase 2 trials of the drug were presented by drugmaker Dr. Reddy’s Laboratories (Hyderabad, India) to the Indian government’s expert panel which has asked the company to conduct Phase 3 clinical trial of 2-DG. The three-month Phase 2 trial of 2-DG involving 40 patients aged between 18 to 65 years was conducted to evaluate the safety and efficacy for acute treatment of moderate to severe COVID-19 patients. However, the expert panel found the sample size of the Phase 2 trial to be inadequate for granting the drug market authorization and has asked Dr. Reddy’s to submit a protocol for Phase 3 trial.

Related Links:
Dr. Reddy’s Laboratories

Print article


Copyright © 2000-2020 Globetech Media. All rights reserved.